Fibrin sealant enables tubeless percutaneous stone surgery

Mark W. Noller, Steven M. Baughman, Allen F. Morey, Brian K. Auge

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose: Fibrin sealant has been demonstrated to be safe and effective as a hemostatic agent and urinary tract sealant. We assessed the ability of fibrin sealant to facilitate tubeless management after uncomplicated percutaneous nephrolithotomy (PCNL). Materials and Methods: Eight consecutive patients underwent single access tubeless PCNL for renal calculi in a total of 9 renal units in a 2-month period. An additional patient with distal ureteral obstruction underwent antegrade ureteroscopy for an 8 × 8 mm distal ureteral stone. Average patient age was 47 years and mean stone size was 3.37 cm2 (range 0.64 to 9.90). Following complete stone clearance a Double-J (Medical Engineering Corp., New York, New York) ureteral stent was placed antegrade and 2 cc HEMASEEL APR (Haemacure Corp., Sarasota, Florida) fibrin sealant was injected under nephroscopic or fluoroscopic visualization into the parenchymal defect just within the renal capsule. Preoperative and postoperative hematocrit (HCT) was determined. Computerized tomography was performed on postoperative day 1 or 2 to evaluate retained stone fragments, perinephric fluid and urinary extravasation. Results: In the 10 renal units treated via this tubeless technique no intraoperative or postoperative complications were noted. Average hospital stay was 1.1 days. All patients were discharged home on postoperative day 1 except 1 undergoing asynchronous bilateral PCNL on consecutive days. The mean intraoperative change in HCT was 2.8%. There was no significant change in HCT on postoperative day 1. No patient required transfusion. Seven renal units and 1 ureteral unit had no residual stone fragments for a complete stone-free rate of 80%. No gross leakage was observed on dressings and postoperative computerized tomography failed to demonstrate urinary extravasation. Conclusions: Tubeless PCNL using fibrin sealant at the renal parenchymal defect appears to be safe and feasible. Further experience is necessary to determine the role of fibrin sealant in percutaneous renal surgery.

Original languageEnglish (US)
Pages (from-to)166-169
Number of pages4
JournalJournal of Urology
Volume172
Issue number1
DOIs
StatePublished - Jul 2004

Fingerprint

Fibrin Tissue Adhesive
Percutaneous Nephrostomy
Kidney
Hematocrit
Tomography
Ureteroscopy
Ureteral Obstruction
Kidney Calculi
Intraoperative Complications
Hemostatics
Bandages
Urinary Tract
Capsules
Stents
Length of Stay

Keywords

  • Fibrin tissue adhesive
  • Kidney
  • Kidney calculi
  • Nephrostomy, percutaneous

ASJC Scopus subject areas

  • Urology

Cite this

Fibrin sealant enables tubeless percutaneous stone surgery. / Noller, Mark W.; Baughman, Steven M.; Morey, Allen F.; Auge, Brian K.

In: Journal of Urology, Vol. 172, No. 1, 07.2004, p. 166-169.

Research output: Contribution to journalArticle

Noller, Mark W. ; Baughman, Steven M. ; Morey, Allen F. ; Auge, Brian K. / Fibrin sealant enables tubeless percutaneous stone surgery. In: Journal of Urology. 2004 ; Vol. 172, No. 1. pp. 166-169.
@article{212dde05295f45d9bcc78888b5bea381,
title = "Fibrin sealant enables tubeless percutaneous stone surgery",
abstract = "Purpose: Fibrin sealant has been demonstrated to be safe and effective as a hemostatic agent and urinary tract sealant. We assessed the ability of fibrin sealant to facilitate tubeless management after uncomplicated percutaneous nephrolithotomy (PCNL). Materials and Methods: Eight consecutive patients underwent single access tubeless PCNL for renal calculi in a total of 9 renal units in a 2-month period. An additional patient with distal ureteral obstruction underwent antegrade ureteroscopy for an 8 × 8 mm distal ureteral stone. Average patient age was 47 years and mean stone size was 3.37 cm2 (range 0.64 to 9.90). Following complete stone clearance a Double-J (Medical Engineering Corp., New York, New York) ureteral stent was placed antegrade and 2 cc HEMASEEL APR (Haemacure Corp., Sarasota, Florida) fibrin sealant was injected under nephroscopic or fluoroscopic visualization into the parenchymal defect just within the renal capsule. Preoperative and postoperative hematocrit (HCT) was determined. Computerized tomography was performed on postoperative day 1 or 2 to evaluate retained stone fragments, perinephric fluid and urinary extravasation. Results: In the 10 renal units treated via this tubeless technique no intraoperative or postoperative complications were noted. Average hospital stay was 1.1 days. All patients were discharged home on postoperative day 1 except 1 undergoing asynchronous bilateral PCNL on consecutive days. The mean intraoperative change in HCT was 2.8{\%}. There was no significant change in HCT on postoperative day 1. No patient required transfusion. Seven renal units and 1 ureteral unit had no residual stone fragments for a complete stone-free rate of 80{\%}. No gross leakage was observed on dressings and postoperative computerized tomography failed to demonstrate urinary extravasation. Conclusions: Tubeless PCNL using fibrin sealant at the renal parenchymal defect appears to be safe and feasible. Further experience is necessary to determine the role of fibrin sealant in percutaneous renal surgery.",
keywords = "Fibrin tissue adhesive, Kidney, Kidney calculi, Nephrostomy, percutaneous",
author = "Noller, {Mark W.} and Baughman, {Steven M.} and Morey, {Allen F.} and Auge, {Brian K.}",
year = "2004",
month = "7",
doi = "10.1097/01.ju.0000129211.71193.28",
language = "English (US)",
volume = "172",
pages = "166--169",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Fibrin sealant enables tubeless percutaneous stone surgery

AU - Noller, Mark W.

AU - Baughman, Steven M.

AU - Morey, Allen F.

AU - Auge, Brian K.

PY - 2004/7

Y1 - 2004/7

N2 - Purpose: Fibrin sealant has been demonstrated to be safe and effective as a hemostatic agent and urinary tract sealant. We assessed the ability of fibrin sealant to facilitate tubeless management after uncomplicated percutaneous nephrolithotomy (PCNL). Materials and Methods: Eight consecutive patients underwent single access tubeless PCNL for renal calculi in a total of 9 renal units in a 2-month period. An additional patient with distal ureteral obstruction underwent antegrade ureteroscopy for an 8 × 8 mm distal ureteral stone. Average patient age was 47 years and mean stone size was 3.37 cm2 (range 0.64 to 9.90). Following complete stone clearance a Double-J (Medical Engineering Corp., New York, New York) ureteral stent was placed antegrade and 2 cc HEMASEEL APR (Haemacure Corp., Sarasota, Florida) fibrin sealant was injected under nephroscopic or fluoroscopic visualization into the parenchymal defect just within the renal capsule. Preoperative and postoperative hematocrit (HCT) was determined. Computerized tomography was performed on postoperative day 1 or 2 to evaluate retained stone fragments, perinephric fluid and urinary extravasation. Results: In the 10 renal units treated via this tubeless technique no intraoperative or postoperative complications were noted. Average hospital stay was 1.1 days. All patients were discharged home on postoperative day 1 except 1 undergoing asynchronous bilateral PCNL on consecutive days. The mean intraoperative change in HCT was 2.8%. There was no significant change in HCT on postoperative day 1. No patient required transfusion. Seven renal units and 1 ureteral unit had no residual stone fragments for a complete stone-free rate of 80%. No gross leakage was observed on dressings and postoperative computerized tomography failed to demonstrate urinary extravasation. Conclusions: Tubeless PCNL using fibrin sealant at the renal parenchymal defect appears to be safe and feasible. Further experience is necessary to determine the role of fibrin sealant in percutaneous renal surgery.

AB - Purpose: Fibrin sealant has been demonstrated to be safe and effective as a hemostatic agent and urinary tract sealant. We assessed the ability of fibrin sealant to facilitate tubeless management after uncomplicated percutaneous nephrolithotomy (PCNL). Materials and Methods: Eight consecutive patients underwent single access tubeless PCNL for renal calculi in a total of 9 renal units in a 2-month period. An additional patient with distal ureteral obstruction underwent antegrade ureteroscopy for an 8 × 8 mm distal ureteral stone. Average patient age was 47 years and mean stone size was 3.37 cm2 (range 0.64 to 9.90). Following complete stone clearance a Double-J (Medical Engineering Corp., New York, New York) ureteral stent was placed antegrade and 2 cc HEMASEEL APR (Haemacure Corp., Sarasota, Florida) fibrin sealant was injected under nephroscopic or fluoroscopic visualization into the parenchymal defect just within the renal capsule. Preoperative and postoperative hematocrit (HCT) was determined. Computerized tomography was performed on postoperative day 1 or 2 to evaluate retained stone fragments, perinephric fluid and urinary extravasation. Results: In the 10 renal units treated via this tubeless technique no intraoperative or postoperative complications were noted. Average hospital stay was 1.1 days. All patients were discharged home on postoperative day 1 except 1 undergoing asynchronous bilateral PCNL on consecutive days. The mean intraoperative change in HCT was 2.8%. There was no significant change in HCT on postoperative day 1. No patient required transfusion. Seven renal units and 1 ureteral unit had no residual stone fragments for a complete stone-free rate of 80%. No gross leakage was observed on dressings and postoperative computerized tomography failed to demonstrate urinary extravasation. Conclusions: Tubeless PCNL using fibrin sealant at the renal parenchymal defect appears to be safe and feasible. Further experience is necessary to determine the role of fibrin sealant in percutaneous renal surgery.

KW - Fibrin tissue adhesive

KW - Kidney

KW - Kidney calculi

KW - Nephrostomy, percutaneous

UR - http://www.scopus.com/inward/record.url?scp=3242769192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242769192&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000129211.71193.28

DO - 10.1097/01.ju.0000129211.71193.28

M3 - Article

C2 - 15201763

AN - SCOPUS:3242769192

VL - 172

SP - 166

EP - 169

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -